Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.72 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.72 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.67 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15649627 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL4741208 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL1059785 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL15649602 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL23833964 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL25183155 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL542910 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL11676490 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL7325048 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL2910119 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| EP-4662197-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024165426-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2024-08-15 | — | — | WO | disclosed |
| EP-4414360-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2024-08-14 | — | — | EP | disclosed |
| US-20170304177-A1 | USE OF ISOSORBIDE ESTER AND N-ACYLATED AMINO ACID DERIVATIVES AS ANTI-AGEING AGENT FOR THE HUMAN SKIN | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2017-10-26 | — | — | US | disclosed |
| EP-3209277-A1 | USE OF ISOSORBIDE ESTER AND N-ACYLATED AMINO ACID DERIVATIVES AS ANTI-AGEING AGENT FOR THE HUMAN SKIN | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2017-08-30 | — | — | EP | disclosed |
| CN-103458873-B | For the aminoacid of the fatty-acylation of oral peptide delivery | NOVO NORDISK A/S (DK) | 2016-04-13 | — | — | CN | disclosed |
| US-20150250882-A1 | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery | NOVO NORDISK HEALTHCARE AG (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2908845-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY | Novo Nordisk Health Care AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014060512-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2014-02-27 | — | — | US | disclosed |
| EP-2696847-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | Novo Nordisk A/S (DK) | 2014-02-19 | — | — | EP | disclosed |
| CN-103458873-A | Fatty acid acylated amino acids for oral peptide delivery | NOVO NORDISK AS | 2013-12-18 | — | — | CN | disclosed |
| WO-2012140155-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2012-10-18 | — | — | WO | disclosed |
| US-6010708-A | TOTAL NUMBER OF CARBONS IN ACYL GROUP IS 13, 15, 17 | KASHIMA OIL COMPANY (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | disclosed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | disclosed |
| US-4016287-A | COSMETIC AND ANTIINFLAMMATORY | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304177-A1 | USE OF ISOSORBIDE ESTER AND N-ACYLATED AMINO ACID DERIVATIVES AS ANTI-AGEING AGENT FOR THE HUMAN SKIN | ARG2, ARGLU1, ASS1 | PLA2G2A 1569/4885PLA2G5 2149/4885NOD1 4566/4885 |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | SLC27A1, SLC27A2, FABP2 | PLA2G2A 324/4885PLA2G5 1585/4885NOD1 3906/4885 |
| US-20150250882-A1 | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery | GHRHR, GHSR, GHITM | PLA2G2A 704/4885PLA2G5 1355/4885NOD1 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.